Supreme Court Dismisses Roche's Challenge, Clears NATCO's Risdiplam Production in India

NATCO Pharma Limited has won the legal battle against F. Hoffmann-La Roche AG at the Supreme Court of India, allowing NATCO to proceed with the production of Risdiplam in India. This ruling brings hope to countless lives debilitated by Spinal Muscular Atrophy (SMA), a leading cause of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company has 9 manufacturing sites and 2 R&D facilities in India, with differentiated manufacturing facilities approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO, and others catering to 50+ global markets.